TAVR Durability at 5 Years in Intermediate Risk Patients

TAVR has been shown beneficial in patients across the risk spectrum. The PARTNER 2 SAPIEN 3 (P2S3i) study on intermediate risk patients was the first to show TAVR superiority vs SAVR when using the transfemoral approach. 

Durabilidad del TAVI a 5 años en pacientes de riesgo intermedio

SAVR durability has been shown in different analysis but, except for a few reports, TAVR durability at long term remains largely untested. Namely, there is no information from large randomized studies. 

P2S3i was analyzed comparing its outcomes vs. PARTNER 2 SAVR patients.

Primary end point was death or disabling stroke.

To account for differences between their populations, patients were matched using propensity score, leaving 783 patients in each group.

Mean patient age was 81, 57% were men, mortality STS score was 5.5%, 35.5% were diabetic, 93% hypertensive, 68% had CAD, 16% had a history of MI, 28% PCI, 26% CABG. 9.2% stroke, 20% had carotid lesions, 6% kidney failure, 28% COPD, 9% cardiomyopathies, and 35% atrial fibrillation. 

Read also: Relationship between Distal Vessel Quality and Outcomes in the Treatment of Chronic Total Occlusions.

AVA was 0.69 cm2, mean gradient 45 mmHg, ejection fraction 57% and mitral regurgitation 12%. 

After 5 years, there were no significant differences in primary end point (40.2% for TAVR vs. 42.7% for SAVR; HR: 0.87; 95% CI: 0.74-1.03; P= 0.10). All-cause mortality was similar (39.2% vs. 41.4%; HR: 0.90; 95% CI: 0.76-1.06; P =0.21), but there was lower incidence of disabling stroke with TAVR (5.8% vs. 7.9%; HR: 0.66; 95% CI: 0.43-1.00; P = 0.0046). This difference was mainly driven by disabling stroke during the first year, with no significant differences thereafter. There were no differences in structural deterioration, bioprosthetic failure, or paravalvular leak, though there was more mild leak among TAVR patients. Aortic valve area was larger among TAVR patients (1.6 cm2 vs.1.4 cm2, p>0.0001), with no differences in mean gradient. 

Read also: Is Edge-to-Edge Treatment with PASCAL Effective at 3 Years?

There were no differences in hospitalization rate or cardiovascular or all-cause death. 

Conclusion

This analysis using propensity score in intermediate risk patients, at 5 years, found death and disabling stroke rates were similar between TAVR and SAVR patients. Structural deterioration in relation to hemodynamic change was similar, but paravalvular leak resulted more common after TAVR with SAPIEN 3. Further assessment of clinical differences and durability of bioprosthetic valves calls for long term followup.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of SAPIEN 3 TranscatheterAortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients.

Reference: Mahesh V. Madhavan, et al. J Am Coll Cardiol 2023;82:109–123.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...